We have previously shown that corneal nerve damage in patients with diabetes assessed using CCM is related to the severity of neuropathy and the extent of intra-epidermal nerve fiber loss in foot skin biopsies (Quattrini et al., 2007, Xin et al, 2015) as well as loss of corneal sensation (Tavakoli et al., 2007). We have also shown that CCM detects early nerve regeneration following pancreas and kidney transplantation (Mehra et al., 2007; Tavakoli 2012). In relation to other neuropathies we have also shown that CCM detects significant nerve fibre damage in patients with Fabry disease (Tavakoli et al., 2009), idiopathic small fiber neuropathy (Tavakoli et al., 2010) and Charcot-Marie-Tooth type 1A (Tavakoli 2012) in the absence of electrophysiological and quantitative sensory testing (QST) abnormalities. We have also shown that CCM can be used to assess corneal innervation with good repeatability (Petropoulos et al. 2012) and rapidly and consistently using our automated image analysis system (ACCMetrics) (Petropoulos et al. 2014). The combination of central cornea and inferior whorl improves the diagnostic efficacy of CCM (Petropoulos et al. 2015). CCM detects neuropathy in patients with impaired glucose tolerance (Asghar et al. 2014) and in patients with T1 diabetes without retinopathy or microalbuminuria (Petropoulos et al. 2015). Therefore CCM offers considerable potential as a surrogate marker, and hence as an end-point for clinical trials of diabetic neuropathy (Tavakoli et al. 2010; Petropoulos et al. 2013).